haven't we run the Ph 1 & Ph II trials ourselves for Trofinetide on Retts syndrome patients, and haven't we conducted our own Ph II trials of NNZ 2591 for Phelan McDermid syndrome ourselves, and have 3 other trials of 2591 currently in progress? It's only the Ph III trials of trofinetide and the commercialisation of that which we've licenced out to a bigger partner in the USA. What's to stop us gradually bringing that expertise and resources in house and conducting our own Ph III trials in future. I'm looking forward to us growing organically as we gain financial strength from our growing royalty revenue and milestone payments.
Share Price, page-8830
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
-0.310(1.54%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.45 | $19.74 | $4.663M | 234.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 507 | $19.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.89 | 765 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |